December 4, 2024 — Rgenta Therapeutics announced that it has entered into a multi-year, multi-target strategic research alliance with pharma giant GSK. The new partners aim to advance the discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology.

Under the terms of the agreement, Rgenta will receive up to $46 million in a cash upfront and pre-option milestone payments. Rgenta has the potential to receive up to nearly $500 million per target in option exercise, research, development, regulatory, and commercial milestone payments plus tiered royalties and a future equity investment. GSK also has an option to expand the alliance to include additional targets. Under the alliance, Rgenta will use its proprietary discovery platform to develop novel oral RNA-targeting small molecule splice modulators against multiple targets nominated by GSK for development. Following GSK's exercise of its options, GSK will be responsible for further development and commercialization of any drug candidates that arise from the alliance.

This alliance highlights the potential of Rgenta's differentiated approach for the discovery and development of oral small molecule splice modulators for high-value targets that until now have been difficult to drug.